• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
By ARMIE MARGARET LEE Oct 24, 2017 | 09:22 AM EDT
Stocks quotes in this article: ALXN, CBIO, DBVT, AIMT

Shares of Alexion Pharmaceuticals Inc. (ALXN) rose 5.3% to $142.37 in premarket trading on Tuesday, Oct. 24, after the New Haven, Conn.-based firm clinched approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults  with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

The announcement on Monday was "largely anticipated by the Street," wrote SunTrust Robinson Humphrey Inc. analyst Yatin Suneja in a note, adding that he nonetheless thinks that the approval "represents a significant de-risking event that should provide a significant growth driver for Soliris."

In addition, "we believe the drug's broad label across all generalized myasthenia gravis patients was a pleasant surprise," Suneja added.

The approval came after the European Commission in August greenlighted the extension of the indication for Soliris to include the treatment of refractory gMG in adults who are anti-AChR antibody-positive. In March, Alexion submitted an application to Japan's Ministry of Labour and Welfare to extend the indication for Soliris as a potential treatment for patients with anti-AchR antibody-positive refractory gMG.

Meanwhile, shares of Catalyst Biosciences Inc. (CBIO) were up 6.1% to $5.20 after the South San Francisco firm entered into a collaboration with privately held Mosaic Biosciences Inc. to develop Catalyst's anti-C3 protease assets for dry age-related macular degeneration (dAMD) and other serious inflammatory retinal disorders.

Among the other biotech movers was DBV Technologies SA (DBVT) . The Montrouge, France-based firm's American depository shares were down 7.2% to $26.28 after closing at $28.32 on Monday, down 41.1%.

DBV on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The company said that the primary endpoint, which assesses the 95% confidence interval (CI) in the difference in response rates between the active and placebo arms, "did not reach the 15% lower bound of the CI that was proposed in the study's Statistical Analysis Plan (SAP) submitted to the U.S Food and Drug Administration (FDA)."

Shares of DBV competitor Aimmune Therapeutics Inc. (AIMT) were down 4.4% to $31.50 in premarket trading on Tuesday after closing at $32.94 on Monday, up 28.4%.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | Global Equity | Healthcare | Drug Approvals

More from Healthcare

Let's See How These Three Dividend Aristocrats Stack Up

Chris Versace
Dec 10, 2019 11:30 AM EST

Two food-related names and one in health care look like promising investments right now.

Cooper Cos. Can Rally Further After Some Sideways Consolidation

Bruce Kamich
Dec 5, 2019 2:42 PM EST

Time to review the charts and indicators.

This Dividend Stock Is Tipping the Scales for Investors

Chris Versace
Dec 5, 2019 2:08 PM EST

As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.

Avita Medical Could Double in 2020 but Not Without Risk

Bruce Kamich
Dec 5, 2019 9:53 AM EST

A 'promising' stock.

Raise Stops on NovoCure

Bruce Kamich
Dec 4, 2019 2:55 PM EST

NVCR's prices are poised to head higher in the months ahead.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:02 AM EST BOB LANG

    Added Some Peleton

    This stock is starting to gain some traction, the ...
  • 01:06 PM EST CAROLYN BORODEN

    MRK and LVS Targets Coming Up

    View Chart » View in New Window »  LVS View C...
  • 12:01 PM EST BOB LANG

    Rolling Up Apple

    Just the other day we added some Apple calls on th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login